- 询价
- 北京美科美生物公司代理TriLink
- 北京美科美生物公司代理TriLink
- 2026年05月28日
13 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
Stocked mRNAs
Nucleoside Triphosphates & Nucleotides
Hot Start PCR & RT-PCR Reagents
Sequencing Reagents
TriLink BioTechnologies 是 Maravai LifeSciences 的一部分，是一家 CDMO，帮助生命科学*导者和创新者克服核酸、NTP 和 mRNA 封盖类似物合成和扩大规模的挑战，具有扩大规模的专业知识和独特的 mRNA 生产能力，包括其专有的 CleanCap ® mRNA 封盖技术。TriLink 继续在其新的全球总部扩大其 cGMP 和通用 mRNA、寡核苷酸和质粒制造能力，以支持治疗、疫苗和诊断客户。
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials. TriLink’s proprietary CleanCap® mRNA co-transcriptional capping technology simplifies mRNA manufacturing by removing additional enzymatic steps, resulting in high capping efficiency and improved yields over traditional co-transcriptional capping methods.
TriLink’s CDMO services offer a range of manufacturing grade products from discovery-grade (RUO) to its customizable intermediate-grade - GMPLink™ to full GMP-grade with scale-up and technology transfer expertise. With its recent facility expansion to increase cGMP capacity, TriLink provides support from initial research phases to the production of material for use in clinical trials. TriLink operates a quality system in compliance with ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards.
TriLink, founded by Dr. Rick Hogrefe, Terry Beck, and Dr. Morteza Vaghefi, has been a pioneer in nucleic acid synthesis & manufacturing since its inception in 1996. With product and service offerings and expertise that have adapted to customer needs over the decades, TriLink remains committed to taking on challenges others simply will not. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new San Diego global headquarters to support therapeutic, vaccine and diagnostic customers.
Nucleoside Triphosphates & Nucleotides
Hot Start PCR & RT-PCR Reagents
Sequencing Reagents
TriLink BioTechnologies 是 Maravai LifeSciences 的一部分，是一家 CDMO，帮助生命科学*导者和创新者克服核酸、NTP 和 mRNA 封盖类似物合成和扩大规模的挑战，具有扩大规模的专业知识和独特的 mRNA 生产能力，包括其专有的 CleanCap ® mRNA 封盖技术。TriLink 继续在其新的全球总部扩大其 cGMP 和通用 mRNA、寡核苷酸和质粒制造能力，以支持治疗、疫苗和诊断客户。
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials. TriLink’s proprietary CleanCap® mRNA co-transcriptional capping technology simplifies mRNA manufacturing by removing additional enzymatic steps, resulting in high capping efficiency and improved yields over traditional co-transcriptional capping methods.
TriLink’s CDMO services offer a range of manufacturing grade products from discovery-grade (RUO) to its customizable intermediate-grade - GMPLink™ to full GMP-grade with scale-up and technology transfer expertise. With its recent facility expansion to increase cGMP capacity, TriLink provides support from initial research phases to the production of material for use in clinical trials. TriLink operates a quality system in compliance with ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards.
TriLink, founded by Dr. Rick Hogrefe, Terry Beck, and Dr. Morteza Vaghefi, has been a pioneer in nucleic acid synthesis & manufacturing since its inception in 1996. With product and service offerings and expertise that have adapted to customer needs over the decades, TriLink remains committed to taking on challenges others simply will not. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new San Diego global headquarters to support therapeutic, vaccine and diagnostic customers.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
北京美科美生物公司代理TriLink
询价
